[go: up one dir, main page]

MA43553B1 - 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES - Google Patents

2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES

Info

Publication number
MA43553B1
MA43553B1 MA43553A MA43553A MA43553B1 MA 43553 B1 MA43553 B1 MA 43553B1 MA 43553 A MA43553 A MA 43553A MA 43553 A MA43553 A MA 43553A MA 43553 B1 MA43553 B1 MA 43553B1
Authority
MA
Morocco
Prior art keywords
compounds
morpholin
naphthyridines
disease
prophylaxis
Prior art date
Application number
MA43553A
Other languages
French (fr)
Other versions
MA43553A (en
Inventor
Gerhard Siemeister
Hans Briem
Knut Eis
Philip Lienau
Wilhelm Bone
Lars Wortmann
Ulrich Lücking
Marcus Koppitz
Benjamin Bader
Julien Lefranc
Joanna Grudzinska-Goebel
Dieter Moosmayer
Uwe Eberspächer
Hans Schick
Nussbaum Franz Von
Antje-Margret Wengner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA43553A publication Critical patent/MA43553A/en
Publication of MA43553B1 publication Critical patent/MA43553B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés 2-(morpholin-4-yl)-1,7-naphtyridine substitués de formule générale (i) ou (ib), des procédés de préparation desdits composés, des composés intermédiaires utiles pour préparer lesdits composés, aux compositions et combinaisons pharmaceutiques comprenant lesdits composés et à l'utilisation desdits composés pour la fabrication d'une composition pharmaceutique pour le traitement ou la prophylaxie d'une maladie, en particulier d'une maladie hyperproliférative en tant qu'agent unique ou en combinaison avec d'autres principes actifs.The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (i) or (ib), processes for the preparation of said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular a hyperproliferative disease as a single agent or in combination with other active ingredients.

MA43553A 2014-08-04 2015-08-03 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES MA43553B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14179692 2014-08-04
MA2015067804 2015-08-03

Publications (2)

Publication Number Publication Date
MA43553A MA43553A (en) 2021-04-21
MA43553B1 true MA43553B1 (en) 2022-01-31

Family

ID=51263279

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43553A MA43553B1 (en) 2014-08-04 2015-08-03 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES

Country Status (2)

Country Link
AR (1) AR101415A1 (en)
MA (1) MA43553B1 (en)

Also Published As

Publication number Publication date
MA43553A (en) 2021-04-21
AR101415A1 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
MA40523B1 (en) 2- (morpholin-4-yl) -1,7-naphthyridines
MA41135B1 (en) Substituted benzamides 1,3-thiazol-2-yl
MA35422B1 (en) Amine-substituted imidazopyridazines
MA45020B1 (en) Aromatic sulfonamide derivatives
MA47447B1 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
CR20210201A (en) New anthelmintic compounds
EA202090448A1 (en) Dihydrooxadiazinones
MA40875A (en) 2,4-DIAMINO-QUINOLEIN SUBSTITUTED AS NEW ANTI-CANCER AGENTS
MA34308B1 (en) SUBSTITUTED TRIAZOLOPYRIDINES
PH12020551891A1 (en) New quinoline derivatives
PH12019502365A1 (en) New bicyclic pyrazole derivatives
WO2017198341A8 (en) Macrocyclic indole derivatives
MA43913A (en) POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC M1 RECEPTOR
MA41174B1 (en) Imidazopyridazine derivatives used as pi3kbeta inhibitors
MA38358A1 (en) Formulations of organic compounds
MA47082B1 (en) Aromatic carboxylic acid amides as bradykinin b1 receptor antagonists
MA43553B1 (en) 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES
MA37849A1 (en) Diazepinone derivatives for use in treating fragile x syndrome, Parkinson's disease or reflux disease
MA38642A1 (en) Pharmaceutical compositions of substituted triazolopyridine compounds for use as anticancer agents
MA38364A1 (en) Substituted imidazopyridazine compounds
MA38774A1 (en) Substituted pyrazolo-pyridinamines inhibitors of mknk1 kinase for use in hyperproliferative and / or angiogenesis disorders.
MA39041B1 (en) Thienopyrimidines as inhibitors of mknk1 and mknk2
MA39256A1 (en) Benzimidazol-2-amines as midh1 inhibitors
FR3042191B1 (en) 1,4,8-TRIAZAPHENANTHRENE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
MA38418A1 (en) New compounds